Sign inJoin waitlistJoin the waitlist

Oliver Sartor

Adjunct Faculty · Tulane University School of Medicine

Credentials: · · · · · · ·

History

Tulane University School of Medicine
Present
Tulane University School of Medicine
Present

Dana-Farber Cancer Institute
2016–2017
Neurology
New York Presbyterian Hospital
2013–2016
Internal Medicine
Tulane University School of Medicine
1983–1986
University of Pennsylvania
1982–1983
Tulane University School of Medicine
1978–1982

Research

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
The Lancet · 2010 · 2,599 citations
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
New England Journal of Medicine · 2021 · First of 21 authors · 2,264 citations
Olaparib for Metastatic Castration-Resistant Prostate Cancer
New England Journal of Medicine · 2020 · 1,879 citations

MM
Michael Morris
40 papers
NS
Neal Shore
34 papers
Brian Lewis
32 papers · 2 as a fellow
Andrew Armstrong
31 papers
CH
Celestia Higano
28 papers
PK
Philip Kantoff
27 papers
Neeraj Agarwal
25 papers
HS
Howard Sandler
24 papers
CS
Christopher Sweeney
23 papers
Emmanuel Antonarakis
23 papers
Felix Feng
22 papers
Jacob Orme
21 papers

Clinical trials

68Ga-PSMA-11 Patients With Newly Diagnosed and Recurrent Prostate Cancer (Firefly)
Principal investigator · No longer available
Tulane University
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2025–2032
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Site PI · Recruiting · Phase 2, Phase 3
Novartis Pharmaceuticals
2025–2033
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2024–2031